Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients

被引:28
|
作者
Morizio, Paige [1 ]
Burkhart, Jena I. [2 ]
Ozawa, Sachiko [1 ,3 ]
机构
[1] Univ N Carolina, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA
[2] UNC Med Ctr, Chapel Hill, NC USA
[3] Univ N Carolina, UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA
关键词
review article; osteoporosis; denosumab; bisphosphonates; cost-effectiveness; adherence; preference; WOMEN SUBOPTIMALLY ADHERENT; RANDOMIZED-OPEN-LABEL; LOW BONE MASS; POSTMENOPAUSAL OSTEOPOROSIS; UNITED-STATES; SATISFACTION; ALENDRONATE; MEDICATION; PREFERENCE; THERAPY;
D O I
10.1177/1060028018768808
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To assess the cost-effectiveness as well as adherence and patient preference for denosumab compared with oral bisphosphonates for the treatment of osteoporosis. Data Sources: Two comprehensive PubMed literature searches (from data inception to December 2017) were performed. The first search included the terms osteoporosis, denosumab, bisphosphonate, and adherence or persistence or compliance or preference. The search terms osteoporosis, denosumab, cost, and effectiveness were used in the second literature search. Additional references were included from reviewing literature citations. Study Selection and Data Extraction: All English-language clinical trials on adherence (as compliance and persistence) or patient preference for denosumab compared with oral bisphosphonates were evaluated. In addition, articles analyzing the cost-effectiveness of denosumab compared with generic alendronate were evaluated. Data Synthesis: Four studies that assessed patient preference showed positive outcomes for preference and satisfaction for subcutaneous use of denosumab every 6 months versus oral alendronate weekly, oral ibandronate monthly, or oral risedronate monthly. Three studies evaluated persistence and compliance and/or adherence and showed improved persistence and compliance rates with denosumab compared with bisphosphonate therapy. Twelve articles and 3 abstracts assessed cost-effectiveness of denosumab compared with generic alendronate. The majority of articles showed that denosumab was cost-effective, and even cost-saving in patients older than 75 years of age and those who have a history of previous fractures, lower bone mineral density T-scores, and more risk factors. Conclusions: Denosumab compared with oral bisphosphonates may improve patient preference and adherence as well as provide a cost-effective treatment strategy, especially among higher-risk and older adults with osteoporosis.
引用
收藏
页码:1031 / 1041
页数:11
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF DENOSUMAB FOR THE TREATMENT OF MALE OSTEOPOROSIS (MOP) IN THE ELDERLY IN SWEDEN
    Parthan, A.
    Deflin, M. M.
    Agodoa, I
    Tao, C. Y.
    Silverman, S. L.
    Orwoll, E.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A446 - A446
  • [32] DENOSUMAB FOR THE TREATMENT OF MALE OSTEOPOROSIS IN THE ELDERLY IN SWEDEN: A COST-EFFECTIVENESS ANALYSIS
    Agodoa, Irene
    Kruse, Morgan
    Parthan, Anju
    Tao, Charles
    Silverman, Stuart
    Orwoll, Eric
    [J]. OSTEOPOROSIS INTERNATIONAL, 2013, 24 : S40 - S40
  • [33] COST-EFFECTIVENESS COMPARISON OF DENOSUMAB AND ZOLEDRONIC ACID IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
    Ding, Y.
    Hay, J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A47 - A47
  • [34] COST-EFFECTIVENESS MODEL FOR DENOSUMAB INCORPORATING FRAX® AND ADHERENCE IN A UK SETTING
    Strom, O.
    Macarios, D.
    Badamgarav, E.
    Borgstrom, F.
    Jonsson, B.
    Tosteson, A.
    Kanis, J.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 20 - 20
  • [35] Cost-effectiveness of bisphosphonates in the prevention of corticosteroid-induced osteoporosis.
    Jacobs, HJ
    Suarez-Almazor, P
    [J]. ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S303 - S303
  • [36] The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
    Ebina, Kosuke
    Hashimoto, Jun
    Kashii, Masafumi
    Hirao, Makoto
    Kaneshiro, Shoichi
    Noguchi, Takaaki
    Tsukamoto, Yasunori
    Yoshikawa, Hideki
    [J]. JOURNAL OF BONE AND MINERAL METABOLISM, 2017, 35 (01) : 91 - 98
  • [37] The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
    Kosuke Ebina
    Jun Hashimoto
    Masafumi Kashii
    Makoto Hirao
    Shoichi Kaneshiro
    Takaaki Noguchi
    Yasunori Tsukamoto
    Hideki Yoshikawa
    [J]. Journal of Bone and Mineral Metabolism, 2017, 35 : 91 - 98
  • [38] The cost-effectiveness of risedronate in the treatment of osteoporosis:: an international perspective
    Borgstrom, F.
    Carlsson, A.
    Sintonen, H.
    Boonen, S.
    Haentjens, P.
    Burge, R.
    Johnell, O.
    Jonsson, B.
    Kanis, J. A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 (07) : 996 - 1007
  • [39] The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective
    F. Borgström
    Å. Carlsson
    H. Sintonen
    S. Boonen
    P. Haentjens
    R. Burge
    O. Johnell
    B. Jönsson
    J. A. Kanis
    [J]. Osteoporosis International, 2006, 17 : 996 - 1007
  • [40] Cost-effectiveness of ibandronate injection IV in the treatment of UK women with postmenopausal osteoporosis who are intolerant to oral bisphosphonates
    Lynch, N. O.
    Earnshaw, S. R.
    Graham, C. N.
    Middelhoven, H.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S11 - S12